Trial site
Affiliated Cancer Hospital of Guangxi Medical University
Nanning, Guangxi 530000, ChinaNot linked to an institution yet
- 7running trials
- 1closed trial
The trials here
What the 8 trials at this site are about, from their registry records.
- Phase
- Phase 35 trials
- Phase 11 trial
- Status
- Recruiting3 trials
- Active, not recruiting2 trials
- Not yet recruiting2 trials
- Completed1 trial
- Lead sponsor
- AbbVie1 trial
- Akeso1 trial
- Alpha Biopharma (Jiangsu) Co., Ltd.1 trial
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1 trial
- Herui Yao1 trial
- and 3 more
Running trials
Recruiting
A Prospective Cohort Study of Zorifertinib as a First-line Treatment in Patients With Epidermal Growth Factor Receptor-mutant Advanced Non-small Cell Lung Cancer With Central Nervous System (CNS) Metastases
NCT07143045· Alpha Biopharma (Jiangsu) Co., Ltd.· Source
Contact: Qitao Yu Professor
Recruiting
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Aihua Tan, Doctor
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263· Phase 3· Akeso· Source
Contact: Jiangqiong Huang, M.D.
Active, not recruiting
A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC
NCT06883630· Phase 1· RemeGen Co., Ltd.· Source
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
NCT07356531· JIANGSU SHENMING Medical Technology CO., Ltd· Source
Contact: Chang Zhao, associate chief physician
Active, not recruiting
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT05445778· Phase 3· AbbVie· Source
Recruiting
Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer
NCT04263298· Phase 3· Herui Yao· Source
Contact: Yongkui Lu, MD
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error